Etiology of cardiovascular disease in patients with schizophrenia: current perspectives

References

• FoleyDLMorleyKISystematic review of early cardiometabolic outcomes of the first treated episode of psychosisArch Gen Psychiatry201168660961621300937
   PubMed Web of Science ®Google Scholar
• CorrellCURobinsonDGSchoolerNRCardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP studyJAMA Psychiatry201471121350136325321337
   PubMed Web of Science ®Google Scholar
• RingenPAEnghJABirkenaesABDiesetIAndreassenOAIncreased mortality in schizophrenia due to cardiovascular disease – a non-systematic review of epidemiology, possible causes, and interventionsFront Psychiatry2014513725309466
   PubMed Web of Science ®Google Scholar
• RyanMCCollinsPThakoreJHImpaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophreniaAm J Psychiatry2003160228428912562574
   PubMed Web of Science ®Google Scholar
• RaphaelTPParsonsJPBlood sugar studies in dementia praecox and manic-depressive insanityArch Neurol Psychiatry19215687709
   Google Scholar
• HansenTIngasonADjurovicSAt-risk variant in TCF7L2 for type II diabetes increases risk of schizophreniaBiol Psychiatry2011701596321414605
   PubMed Web of Science ®Google Scholar
• Le HellardSTheisenFMHaberhausenMAssociation between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?Mol Psychiatry200914330831718195716
   PubMed Web of Science ®Google Scholar
• LiouYJBaiYMLinEGene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychoticsPharmacogenomics J2012121546120877301
   PubMed Web of Science ®Google Scholar
• BaiYMChenTTLiouYJHongCJTsaiSJAssociation between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychoticsSchizophr Res20111252–317918621185157
   PubMed Web of Science ®Google Scholar
• BurghardtKGroveTEllingrodVEndothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophreniaJ Psychopharmacol201428434935624346810
   PubMed Web of Science ®Google Scholar
• ChenXLeeGMaherBSGROUP Investigators; International Schizophrenia ConsortiumGWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophreniaMol Psychiatry201116111117112920838396
   PubMed Web of Science ®Google Scholar
• NicodemusKKLawAJRadulescuEBiological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controlsArch Gen Psychiatry20106710991100120921115
   PubMed Web of Science ®Google Scholar
• MeyerDBirchmeimerCMultiple essential functions of neuregulin in developmentNature199537865583863907477375
   PubMed Web of Science ®Google Scholar
• Huertas-VazquezATeodorescuCReinierKA common missense variant in the neuregulin 1 gene is associated with both schizophrenia and sudden cardiac deathHeart Rhythm201310799499823524320
   PubMed Web of Science ®Google Scholar
• AbergKAdkinsDELiuYGenome-wide association study of antipsychotic-induced QTc interval prolongationPharmacogenomics J201212216517220921969
   PubMed Web of Science ®Google Scholar
• SevenMKaratasOFDuzMBOzenMThe role of miRNAs in cancer: from pathogenesis to therapeutic implicationsFuture Oncol20141061027104824941988
   PubMed Web of Science ®Google Scholar
• de BartolomeisAIasevoliFTomasettiCBuonaguroEFMicroRNAs in schizophrenia: implications for synaptic plasticity and dopamine-glutamate interaction at the postsynaptic density. New avenues for antipsychotic treatment under a theranostic perspectiveMol Neurobiol Epub20141114
   Web of Science ®Google Scholar
• PerkinsDOJeffriesCDJarskogLFmicroRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorderGenome Biol200782R2717326821
   PubMed Web of Science ®Google Scholar
• GardinerEBeveridgeNJWuJQImprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cellsMol Psychiatry201217882784021727898
   PubMed Web of Science ®Google Scholar
• SantarelliDMLiuBDuncanCEGene-microRNA interactions associated with antipsychotic mechanisms and the metabolic side effects of olanzapinePsychopharmacology (Berl)20132271677823318695
   PubMed Web of Science ®Google Scholar
• GamiASWittBJHowardDEMetabolic syndrome and risk of incidence cardiovascular events and death: a systematic review and meta-analysis of longitudinal studiesJ Am Coll Cardiol200749440341417258085
   PubMed Web of Science ®Google Scholar
• HanleyAJKarterAJWilliamsKPrediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the insulin resistance atherosclerosis studyCirculation2005112243713372116344402
   PubMed Web of Science ®Google Scholar
• SaddichhaSManjunathaNAmeenSAkhtarSEffect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective studyJ Clin Psychiatry200768111793179818052574
   PubMed Web of Science ®Google Scholar
• ZhangZJYaoZJLiuWFangQReynoldsGPEffects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophreniaBr J Psychiatry2004184586214702228
   PubMed Web of Science ®Google Scholar
• RyanMCFlanaganSKinsellaUKeelingFThakoreJHThe effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naïve patients with schizophreniaLife Sci200474161999200814967195
   PubMed Web of Science ®Google Scholar
• FleischhackerWWSiuCOBodénREUFEST Study GroupMetabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia TrialInt J Neuropsychopharmacol201316598799523253821
   PubMed Web of Science ®Google Scholar
• MitchellAJVancampfortDSweersKvan WinkelRYuWDe HertMPrevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders – a systematic review and meta-analysisSchizophr Bull201339230631822207632
   PubMed Web of Science ®Google Scholar
• Van GaalLFLong-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposityEur Neuropsychopharmacol200616suppl 3S142S14816863690
   PubMed Web of Science ®Google Scholar
• FordESGilesWHDietzWHPrevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination surveyJAMA2002287335635911790215
   PubMed Web of Science ®Google Scholar
• McEvoyJPMeyerJMGoffDCPrevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES IIISchizophr Res2005801193216137860
   PubMed Web of Science ®Google Scholar
• GoffDCSullivanLMMcEvoyJPA comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controlsSchizophr Res2005801455316198088
   PubMed Web of Science ®Google Scholar
• DixonLWeidenPDelahantyJPrevalence and correlates of diabetes in national schizophrenia samplesSchizophr Bull200026490391211087022
   PubMed Web of Science ®Google Scholar
• KuehnBMQuestionable antipsychotic prescribing remains common, despite serious risksJAMA2010303161582158420424239
   PubMed Web of Science ®Google Scholar
• RaedlerTJCardiovascular aspects of antipsychoticsCurr Opin Psychiatry201023657458120838345
   PubMed Web of Science ®Google Scholar
• ArranzBSanLDueñasRMLower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patientsHum Psychopharmacol2007221111517191265
   PubMed Web of Science ®Google Scholar
• McEvoyJPLiebermanJAPerkinsDOEfficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparisonAm J Psychiatry200716471050106017606657
   PubMed Web of Science ®Google Scholar
• HäggSLindblomYMjörndalTAdolfssonRHigh prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophreniaInt Clin Psychopharmacol2006212939816421460
   PubMed Web of Science ®Google Scholar
• BärKJCardiac autonomic dysfunction in patients with schizophrenia and their healthy relatives – a small reviewFront Neurol2015613926157417
   PubMed Web of Science ®Google Scholar
• EmulMDalkiranMCoskunOP wave and QT changes among inpatients with schizophrenia after parenteral ziprasidone administrationPharmacol Res200960536937219647079
   PubMed Web of Science ®Google Scholar
• ToichiMKubotaYMuraiTThe influence of psychotic states on the autonomic nervous system in schizophreniaInt J Psychophysiol19993121471549987060
   PubMed Web of Science ®Google Scholar
• BärKJBergerSMetznerMAutonomic dysfunction in unaffected first-degree relatives of patients suffering from schizophreniaSchizophr Bull20103651050105819366982
   PubMed Web of Science ®Google Scholar
• JindalRDKeshavanMSEklundKStevensAMontroseDMYeraganiVKBeat-to-beat heart rate and QT interval variability in first episode neuroleptic-naïve psychosisSchizophr Res20091132–317618019570654
   PubMed Web of Science ®Google Scholar
• Valkonen-KorhonenMTarvainenMPRanta-AhoPHeart rate variability in acute psychosisPsychophysiology200340571672614696725
   PubMed Web of Science ®Google Scholar
• VrtovecBStarcVStarcRBeat-to-beat QT interval variability in coronary patientsJ Electrocardiol200033211912510819405
   PubMed Web of Science ®Google Scholar
• ChungAKChuaSEEffects on prolongation of Bazett’s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysisJ Psychopharmacol201125564666620826552
   PubMed Web of Science ®Google Scholar
• WitchelHJHancoxJCNuttDJPsychotropic drugs, cardiac arrhythmia and sudden deathJ Clin Psychopharmacol2003231587712544377
   PubMed Web of Science ®Google Scholar
• ZemrakWRKennaGAAssociation of antipsychotic and antidepressant drugs with Q-T interval prolongationAm J Health Syst Pharm200865111029103818499875
   PubMed Web of Science ®Google Scholar
• ZhaoTParkTWYangJCEfficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trialInt Clin Psychopharmacol201227418419022426471
   PubMed Web of Science ®Google Scholar
• ReillyJGAyisSAFerrierINJonesSJThomasSHQTc-interval abnormalities and psychotropic drug therapy in psychiatric patientsLancet200035592091048105210744090
   PubMed Web of Science ®Google Scholar
• WarnerJPBarnesTRHenryJAElectrocardiographic changes in patients receiving neuroleptic medicationActa Psychiatr Scand19969343113138712033
   PubMed Web of Science ®Google Scholar
• HarriganEPMiceliJJAnzianoRA randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibitionJ Clin Psychopharmacol2004241626914709949
   PubMed Web of Science ®Google Scholar
• YangFDWangXQLiuXPSex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychoticsPsychopharmacology (Berl)2011216191621301815
   PubMed Web of Science ®Google Scholar
• SuzukiYSugaiTFukuiNSex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophreniaHum Psychopharmacol201328321521923553637
   PubMed Web of Science ®Google Scholar
• OzekiYFujiiKKurimotoNQTc prolongation and antipsychotic medications in a sample of 1,017 patients with schizophreniaProg Neuropsychopharmacol Biol Psychiatry201034240140520079791
   PubMed Web of Science ®Google Scholar
• Ramos-RíosRArrojo-RomeroMPaz-SilvaEQTc interval in a sample of long-term schizophrenia inpatientsSchizophr Res20101161354319892525
   PubMed Web of Science ®Google Scholar
• HasnainMViewegWVQTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive reviewCNS Drugs2014281088792025168784
   PubMed Web of Science ®Google Scholar
• SuzukiYOnoSTsuneyamaNEffects of olanzapine on the PR and QT intervals in patients with schizophreniaSchizophr Res2014152131331424275577
   PubMed Web of Science ®Google Scholar
• ChengSKeyesMJLarsonMGLong-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular blockJAMA2009301242571257719549974
   PubMed Web of Science ®Google Scholar
• BayarREmülMTuranSElectrocardiographical P wave changes after electroconvulsive therapy in patients with schizophrenia: a preliminary studyJ ECT2009251263018665103
   PubMed Web of Science ®Google Scholar
• TiihonenJLönnqvistJWahlbeckK11-Year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)Lancet2009374969062062719595447
   PubMed Web of Science ®Google Scholar
• La GrenadeLGrahamDTrontellAMyocarditis and cardiomyopathy associated with clozapine use in the United StatesN Engl J Med2001345322422511463031
   PubMed Web of Science ®Google Scholar
• AlawamiMWasywichCCicovicAKenediCA systematic review of clozapine induced cardiomyopathyInt J Cardiol2014176231532025131906
   PubMed Web of Science ®Google Scholar
• ReindersJParsonageWLangeDPotterJMPleverSClozapine related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric serviceAust N Z J Psychiatry20043811–1291592215555025
   PubMed Web of Science ®Google Scholar
• De BerardisDSerroniNCampanellaDUpdate on the adverse effects of clozapine: focus on myocarditisCurr Drug Saf201271556222663959
   PubMedGoogle Scholar
• BrakouliasVBannanECohenPGearyGAmisulpride and cardiomyopathyAust N Z J Psychiatry200539873816050932
   PubMed Web of Science ®Google Scholar
• BushABurgessCFatal cardiomyopathy due to quetiapineN Z Med J20081211268U290918256721
   PubMedGoogle Scholar
• Roesch-ElyDVan EinsiedelRKathöferSSchwaningerMWeisbrodMMyocarditis with quetiapineAm J Psychiatry200215991607160812202290
   PubMed Web of Science ®Google Scholar
• CoffeySWilliamsMQuetiapine-associated cardiomyopathyN Z Med J2011124133710510721946883
   PubMedGoogle Scholar
• BhatiaMSGuptaRDhawanJMyocarditis after overdose of conventional antipsychoticsWorld J Biol Psychiatry2009104 pt 260660817965989
   PubMed Web of Science ®Google Scholar
• MartiVSudden cardiac death due to risperidone therapy in a patient with possible hypertrophic cardiomyopathyAnn Pharmacother200539597315827070
   PubMed Web of Science ®Google Scholar
• TayJKTanCHChongSATanECFunctional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophreniaProg Neuropsychopharmacol Biol Psychiatry20073161297130217611010
   PubMed Web of Science ®Google Scholar
• ChristoforouNMillerRAHillCMJieCCMcCallionASGearhartJDMouse ES cell-derived cardiac precursor cells are multipotent and facilitate identification of novel cardiac genesJ Clin Invest2008118389490318246200
   PubMed Web of Science ®Google Scholar
• AndreassenOAThompsonWKDaleAMBoosting the power of schizophrenia genetics by leveraging new statistical toolsSchizophr Bull2014401131724319118
   PubMed Web of Science ®Google Scholar
• AndreassenOADjurovicSThompsonWKInternational Consortium for Blood Pressure GWAS, Diabetes Genetics Replication and Meta-analysis Consortium, Psychiatric Genomics Consortium Schizophrenia Working GroupImproved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factorsAm J Hum Genet201392219720923375658
   PubMed Web of Science ®Google Scholar
• RayWAChungCPMurrayKTHallKSteinCMAtypical antipsychotic drugs and the risk of sudden cardiac deathN Engl J Med2009360322523519144938
   PubMed Web of Science ®Google Scholar
• van NoordCDörrMSturkenboomMCThe association of serum testosterone levels and ventricular repolarizationEur J Epidemiol2010251212819957021
   PubMed Web of Science ®Google Scholar
• GuptaPPatelCPatelHT (p-e)/QT ratio as an index of arrhythmogenesisJ Electrocardiol20084156757418790499
   PubMed Web of Science ®Google Scholar